Neurogene (NGNE) FCF Margin (2018 - 2024)
Neurogene's (NGNE) quarterly FCF Margin came in at 1759.68% in Q2 2024, down 269293.09% on a QoQ basis from 0.65% in Q3 2019.
Neurogene (NGNE) FCF Margin (2018 - 2024) Analysis & Trends
Neurogene (NGNE) has 3 years of FCF Margin data on file, last reported at 1759.68% in Q2 2024.
- Quarterly FCF Margin changed N/A year-over-year to 1759.68% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 8042.05% (down 82043.0% YoY) and the FY2024 annual result came in at 7711.24%, changed N/A from the prior year.
- FCF Margin slipped to 1759.68% in Q2 2024, from 0.65% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1759.68% in Q2 2024 to a low of 1759.68% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1,759.68% |
| Sep 30, 2019 | -0.65% |
| Jun 30, 2018 | 36.61% |